ESMO 2019: ADAPTeR study to evaluate the role of nivolumab before and after surgery – results of biomarker analysis

Results from the ADAPTeR study to evaluate the role of anti-PD1 checkpoint inhibitors before and after surgery in patients with advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend.

ADAPTeR is a single centre study in which metastatic RCC patients were treated with nivolumab both before and after nephrectomy until the cancer started to progress. Tumour biopsies were obtained at baseline, on-treatment (week 9) and at progressive disease. Biomarkers of response to nivolumab were assessed using sequencing and evaluation of the immune cells (lymphocytes) within the tumour.

In conclusion:

Read more in UroToday here

Share this Post!

Related post